Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

Globally, an estimated 71 million people have chronic hepatitis C virus (HCV) infection.[1] HCV treatment was interferon-based for more than two decades, with the addition of ribavirin,[2] pegylated-interferon,[3] and first-generation protease inhibitor direct acting antiviral (DAA) therapies (telaprevir, boceprevir),[4,5] providing stepwise improvements in efficacy as defined by sustained virological response (SVR). Despite these improvements, treatment uptake remained low in most countries, with

Source: Journal of Hepatology - October 22, 2019 Category: Gastroenterology Authors: Gregory J. Dore, Jordan J Feld, Alex Thompson, Marianne Martinello, Andrew J. Muir, Kosh Agarwal, Beat M üllhaupt, Heiner Wedemeyer, Karine Lacombe, Gail V. Matthews, Michael Schultz, Marina Klein, Christophe Hezode, Gerard Estivill Mercade, Danny Kho, K Source Type: research